JAMA Network Home
Sign In
Viewpoint

Cannabis Commercialization as a Modifiable Public Health Exposure

JAMA Psychiatry 10.1001/jamapsychiatry.2026.2869

September 16, 2026 at 11:00 AM EDT

Read the full article

This Viewpoint describes how policies shaping cannabis commercialization constitute a modifiable exposure and, thus, may influence psychiatric risk and suggests mitigation strategies.

Corresponding Author: Jodi M. Gilman, Center for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital, 101 Merrimac St, Ste 320, Boston, MA 02114 (jgilman1@mgh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.2869?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091626

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks